Ticlopidine (hydrochloride) -d6

Ticlopidine hydrochloride-d6 is the deuterium labeled Ticlopidine hydrochloride (HY-B0153A) . Ticlopidine (PCR 5332) hydrochloride, an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine hydrochloride blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively[1]. Ticlopidine hydrochloride is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine hydrochloride inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively[2][3].

Product Specifications

CAS Number

[2985259-58-1]

UNSPSC

12352005

Target

Cytochrome P450; Isotope-Labeled Compounds

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

ClC1=C(C([2H])=C(C([2H])=C1C([2H])(N2CC3=C(CC2)SC=C3)[2H])[2H])[2H].Cl

Molecular Formula

C14H9D6Cl2NS

Molecular Weight

306.28

References & Citations

[1]Laura Schäkel, et al. 2-Substituted thienotetrahydropyridine derivatives: Allosteric ectonucleotidase inhibitors. Arch Pharm (Weinheim) . 2021 Dec;354 (12) :e2100300.|[2]I.KRASLOVA1, et al. Ticlopidine-Induced Cholestatic Inflammatory Hepatitis: New Insights into Pathogenetic Mechanisms of Drug-Related Hepatotoxicity. |[3]Si-hyung Yang, et al. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin. 2011 Jul;32 (7) :967-72.|[4]F Piovella, et al. The effect of Ticlopidine on human endothelial cells in culture. Thromb Res. 1984 Feb 1;33 (3) :323-32.